COMMUNIQUÉS West-GlobeNewswire
-
Keros Therapeutics Appoints Charles Newton to its Board of Directors
26/02/2026 -
Biodesix Announces Fourth Quarter and Fiscal Year 2025 Results and Highlights
26/02/2026 -
Emergent BioSolutions Announces New $50 Million Stock Repurchase Program
26/02/2026 -
Denali Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Business Highlights
26/02/2026 -
Bicara Therapeutics Announces Closing of Oversubscribed Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
26/02/2026 -
Pacira BioSciences Reports Fourth Quarter and Full-Year 2025 Financial Results
26/02/2026 -
Cytek Biosciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides 2026 Outlook
26/02/2026 -
FDA approves HERNEXEOS®, the first targeted therapy for adults with HER2-mutant advanced NSCLC as an initial treatment option
26/02/2026 -
HelpAlert Launches Elderly Welfare Check-In App in the United States That Requires No Wearable Device And Is Very Simple To Use.
26/02/2026 -
OSE Immunotherapeutics reçoit un deuxième avis positif du Comité Indépendant de Surveillance des Données (IDMC) pour l’essai pivot de Phase 3 ARTEMIA évaluant Tedopi® dans le cancer du poumon non à petites cellules
26/02/2026 -
Fagron completes strategic acquisition of Pharmavit Europe, strengthening its leadership in high‑growth nutraceutical ingredients across EMEA
26/02/2026 -
Longevity Supplement Primeadine® GF Named 2026 NEXTY Award Finalist by New Hope Network
26/02/2026 -
Full-year 2025 results
26/02/2026 -
Résultats annuels 2025
26/02/2026 -
Regeneron Renews Sponsorship of the Regeneron Science Talent Search Through 2036, Committing an Additional $150 Million to Empower the Next Generation of Science and Technology Leaders
26/02/2026 -
Flourish Research® Announces Strategic Partnership with Capitol Imaging Services and Upcoming Launch of Flourish Imaging™ in Gainesville, Georgia
26/02/2026 -
Regeneron Renews Sponsorship of the Regeneron Science Talent Search Through 2036, Committing an Additional $150 Million to Empower the Next Generation of Science and Technology Leaders
26/02/2026 -
GENFIT Reports Fourth Quarter 2025 Financial Information and Provides a Corporate Update
26/02/2026 -
Curium Announces Pharmacokinetics and Dosimetry Data for Investigational Lutetium-177 Zadavotide Guraxetan in Metastatic Castration-Resistant Prostate Cancer at ASCO GU 2026
26/02/2026
Pages